COMPANY

Alkeus Pharmaceuticals

Status: Acquired, now part of Tarsus Pharmaceuticals · How status works

2 open jobs · last seen Oct 23, 2026 · 6 sources

Our therapeutic approach aims to prevent the accumulation of toxic vitamin A dimers in the retina, which are associated with Stargardt disease and geographic atrophy secondary to age-related macular degeneration. Our oral investigational therapy is a new molecular entity designed to reduce vi From company website Source · Oct 12, 2026

Keywords: Stargardt Macular Degeneration Stargardt Macular Dystrophy Autosomal Recessive Stargardt Disease 1 (ABCA4-related) Age Related Macular Degeneration AMD Other Retinal Dystrophies ALK-001 ALK-001 (No generic name)

Profile checked Oct 10, 2026

2Open jobs 5Trials (company is sponsor)

Hiring

Title	Location (from posting)	Employer posted	First seen
Manager II, Clinical Studies	Cambridge, MA	Oct 20, 2026	Oct 21, 2026
General Interest	Cambridge, MA	Oct 16, 2024	Oct 5, 2026

See all 2 jobs

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (2 open jobs at last check). source ↗
Jun 3, 2026 Trial start Phase 3: Study of ALK-001 on the Progression of Stargardt Disease source ↗
Dec 20, 2019 Trial start Phase 2: Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) source ↗
May 7, 2019 Trial start 2: Phase 2/3 Study of ALK-001 in Geographic Atrophy source ↗
2015-08 Trial start 2: Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease source ↗
2014-04 Trial start 1: Phase 1 Safety Study of ALK-001 in Healthy Volunteers source ↗

Upcoming milestones

Jun 30, 2028 (ESTIMATED) · 2 · Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease · NCT02402660
2028-12 (ESTIMATED) · Phase 2 · Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) · NCT04239625
2029-10 (ESTIMATED) · Phase 3 · Study of ALK-001 on the Progression of Stargardt Disease · NCT07419334

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 2

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Manager II, Clinical Studies	Cambridge, MA	Oct 20, 2026	Oct 21, 2026	Not stated
General Interest	Cambridge, MA	Oct 16, 2024	Oct 5, 2026	Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT02402660	Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease	2	Active, not recruiting	2015-08	Jun 30, 2028 (estimated)
NCT04239625	Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)	Phase 2	Active, not recruiting	Dec 20, 2019	2028-12 (estimated)
NCT07419334	Study of ALK-001 on the Progression of Stargardt Disease	Phase 3	Recruiting	Jun 3, 2026	2029-10 (estimated)
NCT03845582	Phase 2/3 Study of ALK-001 in Geographic Atrophy	2	Completed	May 7, 2019	Jul 25, 2023 (actual)
NCT02230228	Phase 1 Safety Study of ALK-001 in Healthy Volunteers	1	Completed	2014-04	2014-09 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of Sofinnova Investments (captured Oct 12, 2026). portfolio page ↗
InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗

Connect

See your connections at Alkeus Pharmaceuticals on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18